This week, five pharmaceutical stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
NuPathe Inc. (PATH) is bettering its rating of C (“hold”) from last week to a B (“buy”) this week. NuPathe develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, PATH also gets A’s. For more information, get Portfolio Grader’s complete analysis of PATH stock.
The rating of GW Pharmaceuticals PLC Sponsored ADR (GWPH) moves up this week, rising from a C to a B. For more information, get Portfolio Grader’s complete analysis of GWPH stock.
This week, Watson Pharmaceuticals (WPI) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
Cardiome Pharma (CRME) shows solid improvement this week. The company’s rating rises from a C to a B. Cardiome Pharma focuses on the discovery, development, and commercialization of drugs to treat or prevent cardiovascular and other diseases. Shares of the stock have been trading at an exceptionally rapid pace, up 567.8% from the week prior. For more information, get Portfolio Grader’s complete analysis of CRME stock.
AbbVie, Inc.’s (ABBV) ratings are looking better this week, moving up to a B from last week’s C. AbbVie, a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. Shares of the stock have been trading at an exceptionally rapid pace, up threefold from the week prior. The stock’s dividend yield is 2%. For more information, get Portfolio Grader’s complete analysis of ABBV stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
